Results 21 to 30 of about 76,229 (261)
Radiofluorination of a highly potent ATM inhibitor as a potential PET imaging agent
EJNMMI Research, 2022 Abstract Purpose Ataxia telangiectasia mutated (ATM) is a key mediator of the DNA damage response, and several ATM inhibitors (ATMi) are currently undergoing early phase clinical trials for the treatment of cancer. A radiolabelled ATMi to determine drug pharmacokinetics could assist patient selection in a move towards ...
Fraser, CR +11 more
openaire +5 more sources
Prostate Cancer-Specific Positron Emission Tomography with Different Radiotracers. [PDF]
Egyptian Journal of Nuclear Medicine, 2020 Imaging evaluation of prostate cancer needs to be tailored for various radiopharmaceuticals being remarkably heterogeneous disease. Positron emission tomography (PET) has played a relatively limited role in prostate cancer imaging.
Alshemeili, M.
doaj +1 more source
FDG-PET imaging for the evaluation of antiglioma agents in a rat model [PDF]
Neuro-Oncology, 2008 The increasing development of novel anticancer agents demands parallel advances in the methods used to rapidly assess their therapeutic efficacy (TE) in the preclinical phase. We evaluated the ability of small-animal PET, using the (18)F-fluoro-deoxy-D-glucose (FDG) radiotracer, to predict the TE of a number of anticancer agents in the rat C6 glioma ...
Sarah, Assadian +4 more
openaire +2 more sources
Acta Pharmaceutica Sinica B, 2023 To expand the single-dose duration over which noninvasive clinical and preclinical cancer imaging can be conducted with high sensitivity, and well-defined spatial and temporal resolutions, a facile strategy to prepare ultrasmall nanoparticulate X-ray ...
Lu Su +13 more
doaj +1 more source
Positron Emission Tomography Probes for Imaging Cytotoxic Immune Cells
Pharmaceutics, 2022 Non-invasive positron emission tomography (PET) imaging of immune cells is a powerful approach for monitoring the dynamics of immune cells in response to immunotherapy.
Ala Amgheib, Ruisi Fu, Eric O. Aboagye
doaj +1 more source
Pharmaceutics, 2019 Porphyrins are known therapeutic agents for photodynamic therapy of cancer and also imaging agents for NIR fluorescence imaging, MRI, or PET. A combination of interesting features makes tetrapyrrolic macrocycles suitable for use as theranostic agents ...
Bruno F. O. Nascimento +4 more
doaj +1 more source
Metal-Based Complexes as Pharmaceuticals for Molecular Imaging of the Liver
Pharmaceuticals, 2019 This article reviews the use of metal complexes as contrast agents (CA) and radiopharmaceuticals for the anatomical and functional imaging of the liver.
Julia Greiser +2 more
doaj +1 more source
Update on the Use of PET/MRI Contrast Agents and Tracers in Brain Oncology: A Systematic Review
International Journal of Nanomedicine, 2022 Alessio Smeraldo,1– 3,* Alfonso Maria Ponsiglione,1,* Andrea Soricelli,4 Paolo Antonio Netti,1– 3 Enza Torino1– 3 1Department of Chemical, Materials and Production Engineering, University of Naples “Federico II”, Naples, 80125, Italy ...
Smeraldo A +4 more
doaj
Radiolabeled Iron Oxide Nanoparticles as Dual Modality Contrast Agents in SPECT/MRI and PET/MRI
Nanomaterials, 2023 During the last decades, the utilization of imaging modalities such as single photon emission computed tomography (SPECT), positron emission tomography (PET), and magnetic resonance imaging (MRI) in every day clinical practice has enabled clinicians to ...
Maria-Argyro Karageorgou +3 more
doaj +1 more source
EJNMMI Research, 2021 Background Animal brain functions evaluated by in vivo imaging under anesthesia can be affected by anesthetic agents, resulting in incorrect assessment of physiological brain function.
Chie Suzuki +2 more
doaj +1 more source